| John Paul Davis, NP | |
|
Hi-desert Medical Center, 6601 White Feather Road, Joshua Tree, CA 92252 | |
| (760) 366-3711 | |
| Not Available |
| Full Name | John Paul Davis |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Location | Hi-desert Medical Center, Joshua Tree, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760426449 | NPI | - | NPPES |
| RN85634 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 15101 (California) | Secondary |
| 363L00000X | Nurse Practitioner | 15101 (California) | Primary |
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
Kaydon Corporation today announced that it has completed the acquisition of all of the outstanding shares of HAHN-Gasfedern GmbH and related real estate and intangible property ("Hahn") from Ulrich Hahn e.K. pursuant to the definitive agreement announced on February 25, 2011.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
The Institute of Medicine today awarded the 2013 Rhoda and Bernard Sarnat International Prize in Mental Health to William T. Carpenter, professor of psychiatry and pharmacology at the University of Maryland School of Medicine, Baltimore.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Paul Davis, NP 719 Cedar View Dr, Beaumont, CA 92223-6417 Ph: () - | John Paul Davis, NP Hi-desert Medical Center, 6601 White Feather Road, Joshua Tree, CA 92252 Ph: (760) 366-3711 |
News Archive
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
Kaydon Corporation today announced that it has completed the acquisition of all of the outstanding shares of HAHN-Gasfedern GmbH and related real estate and intangible property ("Hahn") from Ulrich Hahn e.K. pursuant to the definitive agreement announced on February 25, 2011.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
The Institute of Medicine today awarded the 2013 Rhoda and Bernard Sarnat International Prize in Mental Health to William T. Carpenter, professor of psychiatry and pharmacology at the University of Maryland School of Medicine, Baltimore.
› Verified 6 days ago